chr12-51789350-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PP2PP3_ModeratePP5_Very_Strong
The NM_001330260.2(SCN8A):c.4351G>A(p.Gly1451Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 31)
Consequence
SCN8A
NM_001330260.2 missense
NM_001330260.2 missense
Scores
15
3
1
Clinical Significance
Conservation
PhyloP100: 10.0
Genes affected
SCN8A (HGNC:10596): (sodium voltage-gated channel alpha subunit 8) This gene encodes a member of the sodium channel alpha subunit gene family. The encoded protein forms the ion pore region of the voltage-gated sodium channel. This protein is essential for the rapid membrane depolarization that occurs during the formation of the action potential in excitable neurons. Mutations in this gene are associated with cognitive disability, pancerebellar atrophy and ataxia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 13 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), SCN8A. . Gene score misZ 0.78755 (greater than the threshold 3.09). Trascript score misZ 10.436 (greater than threshold 3.09). GenCC has associacion of gene with myoclonus, familial, 2, infantile convulsions and choreoathetosis, cognitive impairment with or without cerebellar ataxia, undetermined early-onset epileptic encephalopathy, complex neurodevelopmental disorder, developmental and epileptic encephalopathy, 13, benign familial infantile epilepsy, seizures, benign familial infantile, 5.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.937
PP5
Variant 12-51789350-G-A is Pathogenic according to our data. Variant chr12-51789350-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 192318.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-51789350-G-A is described in Lovd as [Pathogenic]. Variant chr12-51789350-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SCN8A | NM_001330260.2 | c.4351G>A | p.Gly1451Ser | missense_variant | 24/27 | ENST00000627620.5 | NP_001317189.1 | |
SCN8A | NM_014191.4 | c.4351G>A | p.Gly1451Ser | missense_variant | 24/27 | ENST00000354534.11 | NP_055006.1 | |
SCN8A | NM_001177984.3 | c.4228G>A | p.Gly1410Ser | missense_variant | 23/26 | NP_001171455.1 | ||
SCN8A | NM_001369788.1 | c.4228G>A | p.Gly1410Ser | missense_variant | 23/26 | NP_001356717.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN8A | ENST00000354534.11 | c.4351G>A | p.Gly1451Ser | missense_variant | 24/27 | 1 | NM_014191.4 | ENSP00000346534.4 | ||
SCN8A | ENST00000627620.5 | c.4351G>A | p.Gly1451Ser | missense_variant | 24/27 | 5 | NM_001330260.2 | ENSP00000487583.2 | ||
SCN8A | ENST00000599343.5 | c.4384G>A | p.Gly1462Ser | missense_variant | 23/26 | 5 | ENSP00000476447.3 | |||
SCN8A | ENST00000355133.7 | c.4228G>A | p.Gly1410Ser | missense_variant | 22/25 | 1 | ENSP00000347255.4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 genomes
Cov.:
31
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 31
GnomAD4 genome
Cov.:
31
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6Uncertain:1Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Developmental and epileptic encephalopathy, 13 Pathogenic:3Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Mar 22, 2022 | The variant has been previously reported as de novo in a similarly affected individual (PMID: 25725044). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:25725044). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.96>=0.6, 3CNET: 0.973>=0.75). A missense variant is a common mechanism associated with Developmental and epileptic encephalopathy 13. It is not observed in the gnomAD v2.1.1 dataset. Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 19, 2023 | Variant summary: SCN8A c.4351G>A (p.Gly1451Ser) results in a non-conservative amino acid change located in the Ion transport domain (IPR005821) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 249572 control chromosomes. c.4351G>A has been reported in the literature as a recurrent de-novo variant in individuals affected with features of SCN8A-related Epileptic Encephalopathy 13 (example, PMID: 25725044, 31026061, 29100083, 27165006). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in an apparent loss of channel activity in HEK cell assay in-vitro (PMID: 25725044). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (Pathogenic, n=4; VUS, n=1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 16, 2021 | The c.4351G>A (p.G1451S) alteration is located in exon 24 (coding exon 23) of the SCN8A gene. This alteration results from a G to A substitution at nucleotide position 4351, causing the glycine (G) at amino acid position 1451 to be replaced by a serine (S). Based on data from the Genome Aggregation Database (gnomAD), the SCN8A c.4351G>A alteration was not observed, with coverage at this position. This alteration has been reported de novo in multiple unrelated patients with epileptic encephalopathy (Blanchard, 2015; Hamdan, 2017; Denis, 2019). The p.G1451 amino acid is conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). Functional analysis demonstrated that the p.G1451S alteration showed decreased current densities (Blanchard, 2015). Using whole-cell patch clamp measurements in HEK293 cells transfected with wildtype or mutated SCN8A cDNA encoding the NaV1.6α subunit, cells expressing wildtype channels exhibited substantial voltage-evoked currents, while current densities in cells expressing the G1451S mutant were about 10-fold smaller than wildtype-transfected cells which was comparable to those in non-transfected cells. The p.G1451S alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 01, 2020 | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been reported to affect SCN8A protein function (PMID: 25725044). This variant has been observed in individual(s) with clinical features of epileptic encephalopathy (PMID: 31026061, 25725044, 29100083). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 192318). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with serine at codon 1451 of the SCN8A protein (p.Gly1451Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 02, 2024 | Published functional studies demonstrate a damaging effect, showing a 10-fold decrease in current density compared to wildtype, consistent with a loss of function (PMID: 25725044); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This substitution is predicted to be within the transmembrane segment S6 of the third homologous domain; This variant is associated with the following publications: (PMID: 25725044, 32090326, 35325842, 27165006, 33915942, 31887642, 30615093, 32916281, 32845893, 29100083, 34979445, 38113761, 26029160, 38250573, 31026061, 35627257, 26900580) - |
not specified Uncertain:1
Uncertain significance, flagged submission | clinical testing | Athena Diagnostics | Dec 20, 2016 | - - |
Complex neurodevelopmental disorder Other:1
not provided, no classification provided | literature only | Channelopathy-Associated Epilepsy Research Center | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;.;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D;.;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;.;.;.;H
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;D;D;.;.
REVEL
Pathogenic
Sift
Uncertain
D;D;D;.;.
Sift4G
Uncertain
D;D;D;D;D
Polyphen
D;.;.;.;.
Vest4
MutPred
Loss of catalytic residue at L1456 (P = 0.1723);.;.;.;Loss of catalytic residue at L1456 (P = 0.1723);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at